Results 41 to 50 of about 5,314 (201)

Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy [PDF]

, 2019
Background: International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST).
Alami, Negar N., Conway, Brian, Dillon, John F., Dore, Gregory J., Dumas, Emily O., Felizarta, Franco, Fredrick, Linda M., Grebely, Jason, Gschwantler, Michael, Hézode, Christophe, Mensa, Federico J., Tomasiewicz, Krzysztof   +11 more
core   +2 more sources

Improving access to direct acting antivirals via a multimodal integrated care program in an addiction medicine clinic

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Injection drug use is a driver of hepatitis C virus (HCV) transmission, thus integrating HCV care into addiction care is likely necessary for HCV elimination. Here we describe how we integrated HCV care into our addiction medicine (AM) clinic and evaluate its effect on HCV treatment.
Arya Zandvakili, Joseph Rattenni, James Burton, Lakshmi Guduguntla, Marcus Osman, Sayeh Sabbagh, Stephan Arndt, Ben Miskle, Quanhathai Kaewpoowat, Michael Ohl, Andrea Weber, Alison Lynch   +11 more
wiley   +1 more source

Curing of chronic hepatitis C combined with coronavirus disease 2019 in a couple over 85 years old: a case series study

Frontiers in Microbiology
IntroductionData on the management of patients aged more than 85 years with chronic hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequential infections are lacking.MethodsThe current study described the ...
Qing-Lei Zeng, Xue-Yan Lv, Ru-Yue Chen, Ya-Jie Pan   +3 more
doaj   +1 more source

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 2; peer review: 3 approved]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Sofosbuvir-velpatasvir en pacientes mexicanos con hepatitis C: una revisión retrospectiva

Revista de Gastroenterología de México, 2022
Resumen: Introducción: La combinación de sofosbuvir-velpatasvir (SOF/VEL) es una terapia antiviral de acción directa que está autorizada y disponible en México.
J.L. Pérez-Hernández, C.A. Arce-Salinas, R. Lehmann-Mendoza, A. Torre-Delgadillo, G.E. Castro-Narro, E. Cerda-Reyes, M.V. Ramos-Gómez, L. Juárez-Chavez, M. Dehesa-Violante, L.E. Muñoz-Espinosa, L.E. Cisneros-Garza, I. Aiza-Haddad, J.A. Velarde-Ruiz-Velasco, R. Contreras-Omaña, N. García-Casarreal, A. Carmona-Castañeda, F. Higuera-De la Tijera   +16 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4 [PDF]

, 2017
[Abstract] Background and Aims. Hepatitis C (HCV) therapy with Sofosbuvir (SOF)/Simeprevir (SMV) in clinical trials and real‐world clinical practice, showed high rates of sustained virological response (SVR) in non‐cirrhotic genotype (GT)‐1 and GT‐4 ...
Arencibia, Ana C., Artaza, Tomás de, Baliellas, Carme, Blasco, Alejandro, Cabezas, Joaquín, Calleja, José L., Carrión, José A., Castellote, José, Castells, Lluis, Castro-Iglesias, Ángeles, Crespo, Javier, Cuervas-Mons Martínez, Valentín, Diago, Moisés, Fernández, Inmaculada, Forns, Xavier, Forné, Monserrat, Gallego, Adolfo, García-Samaniego, Javier, Gea-Rodríguez, Francisco, Giráldez, Álvaro, Gómez, Alexandra, Hontangas, Vanessa, López-Núñez, Carmen, Mariño, Zoe, Montero, José L., Moreno, José M., Morillas, Rosa, Narváez, Isidro, Pascasio-Acevedo, Juan M., Pascual, Sonia, Prieto, Martín, Romero-Gómez, Manuel, Sánchez Ruano, Juan José, Sánchez-Antolín, Gloria, Torras, Xavier, Turnes, Juan, Vergara, Mercedes   +36 more
core   +2 more sources

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, EarlyView.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BMC Gastroenterology, 2020
Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C   +14 more
doaj   +1 more source